EFFECT OF INSULIN TREATMENT INTENSIFICATION WITH INSULIN GLULISINE ADDED TO INSULIN GLARGINE IN TYPE 2 DIABETES PATIENTS IN ROMANIA

被引：0

作者：

Guja, Cristian ^{[1
,2
]}

Ioacara, Sorin ^{[2
,3
]}

Catrinoiu, Doina ^{[4
]}

Negrisanu, Gabriela ^{[5
]}

Popa, Amorin ^{[6
]}

机构：

[1] Prof NC Paulescu Natl Inst Diabet Nutr & Metab Di, Bucharest, Romania

[2] Carol Davila Univ Med & Pharm, Bucharest, Romania

[3] Elias Emergencya Univ Hosp, Dept Diabet & Metab & Dis, Bucharest, Romania

[4] Emergency Clin Cty Hosp, Diabet Clin, Constanta, Romania

[5] Victor Babes Univ Med & Pharm, Timisoara, Romania

[6] Emergency Clin Cty Hosp, Diabet & Internal Med Clin, Oradea, Romania

来源：

INTERDISCIPLINARY APPROACHES IN DIABETIC CHRONIC KIDNEY DISEASE | 2015年

关键词：

diabetes; insulin treatment; insulin glargine; insulin glulisine real-life clinical practice; EUROPEAN ASSOCIATION; BASAL-BOLUS; THERAPY; HYPERGLYCEMIA; MANAGEMENT; STATEMENT;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We aimed to assess in real life setting the effect on glycemic control in T2DM patients of insulin treatment intensification according to the 2008 ADA/EASD algorithm, using insulin glulisine on top of insulin glargine. We analyzed 1707 adult T2DM patients treated with glargine and glulisine for 6 +/- 1 months. Insulin glulisine was added if HbA1c > 7%. Comparison between quantitative variables was made with the Student t test or Fisher exact text using the SPSS v21 software. HbA1c decreased significantly with 1.55% (p<0.001) while mean FBG decreased to 119.2 mg%. Overall 42.6% of patients reached the HbA1c target < 7%. Mean number of documented hypoglycemic episodes (glycaemia < 72 mg/dl) was 0.79/patient. In 1235 patients (72.3%) no hypoglycemic episodes have been registered. In conclusion our data suggest the efficacy and safety of treatment intensification with insulin glulisine in T2DM patients not controlled with glargine basal insulin combined with oral drugs.

引用

页码：230 / 239

页数：10

共 50 条

[31] Comparison of Insulin Glargine with Insulin Degludec in Type 1 Diabetes Patients
Kuroda, Akio
Tsuruo, Miho
Takeshi, Kondo
Aki, Nanako
Oguro, Yukari
Endo, Itsuro
Aihara, Ken-ichi
Tamaki, Motoyuki
Matsumoto, Toshio
Matsuhisa, Munehide
DIABETES, 2014, 63 : A232 - A232
[32] Insulin glargine versus NPH insulin in patients with type 1 diabetes
Ratner, R
DRUGS OF TODAY, 2003, 39 (11) : 867 - 876
[33] Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients
Pan, Chang-Yu
Sinnassamy, Patrick
Chung, Kab-Do
Kim, Kwang-Won
DIABETES RESEARCH AND CLINICAL PRACTICE, 2007, 76 (01) : 111 - 118
[34] Insulin management in overweight or obese type 2 diabetes patients: the role of insulin glargine
Davies, M.
Khunti, K.
DIABETES OBESITY & METABOLISM, 2008, 10 : 42 - 49
[35] Inhaled insulin plus insulin glargine versus biaspart insulin for type 2 diabetes
不详
AFRICAN JOURNAL OF DIABETES MEDICINE, 2010, 18 (02): : 18 - 18
[36] A Cost Comparison of a Basal Bolus Regimen (Insulin Glargine and Insulin Glulisine) with a Conventional Pre-Mixed Insulin Regimen in Type 2 Diabetes Patients-The GINGER Study
Vora, Jiten P.
Van Schalkwyk, Christine
Keech, Martin
DIABETES, 2009, 58 : A120 - A120
[37] Insulin detemir versus insulin glargine for type 2 diabetes mellitus
Swinnen, Sanne G.
Simon, Airin C. R.
Holleman, Frits
Hoekstra, Joost B.
DeVries, J. Hans
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (07):
[38] Insulin detemir versus insulin glargine for type 2 diabetes mellitus
Simon, A. C. R.
Swinnen, S. G.
Holleman, F.
Hoekstra, J. B. L.
DeVries, J. H.
DIABETOLOGIA, 2011, 54 : S420 - S421
[39] Optimizing treatment strategies with insulin glargine in Type 2 diabetes
Owens, David R.
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2012, 7 (04) : 377 - 393
[40] A COST COMPARISON OF A BASAL BOLUS REGIMEN (INSULIN GLARGINE AND INSULIN GLULISINE) WITH A CONVENTIONAL PRE-MIXED INSULIN REGIMEN IN TYPE-2 DIABETES PATIENTS - THE GINGER STUDY
Tilling, C.
Vora, J.
Keech, M.
VALUE IN HEALTH, 2011, 14 (03) : A94 - A94

← 1 2 3 4 5 →